Abbott Laboratories detracted from the Jensen Quality Growth Equity Strategy's performance in the second quarter of 2026 after its stock price declined following first-quarter earnings. Management lowered full-year guidance to reflect dilution from the Exact Sciences acquisition, while the Nutrition and portions of the Diagnostics businesses faced near-term headwinds. Ongoing uncertainty surrounding NEC litigation related to its preterm infant formula also weighed on investor sentiment. These factors overshadowed otherwise strong results, including high-single-digit organic growth in Medical Devices and Established Pharma, which together represented over 62% of first-quarter sales. The stock closed at $103.06 per share on July 24, 2026, with a one-month return of 7.04% and a 52-week loss of 18.43%.
Abbott LaboratoriesManagement lowered full-year guidance due to dilution from Exact Sciences acquisition.